Melinda Rushing, an assistant professor at the Edward J. Bloustein School of Planning and Public Policy in the Health Administration department, was recently awarded a National Institutes of Health Career Development Award to study how to improve Emergency Room treatment of patients with sickle cell disease experiencing painful Vaso Oclusive Crises (VOC).
The grant, funded by the National Heart, Lung and, Blood Institute (NHLBI), will be used toward her research on the Robert Wood Johnson Emergency Department (ED) system to assess how effectively tools for managing VOCs are used in everyday clinical contexts, said Rushing. She plans to document how certain tools from the American Society of Hematology (ASH) could be better utilized, including Individualized Pain Plans that determine a course of action for patients in crisis.
“The study is all around implementation and implementation science,” Rushing said. “How do we improve the way these tools that we know are supposed to be beneficial … how do we improve the way they’re being implemented within a system?”
Rushing described sickle cell disease as patients having C-shaped red blood cells that fail to carry as much oxygen through the body and don’t last as long, causing anemia. She estimated that more than 100,000 people across the U.S. suffer from sickle cell disease, while it primarily affects people in tropical regions, including sub-Saharan Africa, the Mediterranean, India and Latin America. The disease, while relatively prevalent worldwide, is considered “rare” in the United States, she said.
In the U.S., sickle cell disease is diagnosed at birth in routine blood screenings, and it is classified as a chronic condition. Since the disease is not considered a disability in every state, some individuals may not qualify for Medicaid and be forced to end their treatment, Rushing said. She explained that when people diagnosed with sickle cell become adults and lose coverage, the transition within their health insurance status can sometimes be fatal.
“Many individuals (diagnosed with sickle cell disease) are able to survive through childhood, adolescence and into young adulthood,” Rushing said. “We do see a spike in mortality during young adulthood. That’s a combination of the disease being degenerative and progressive.”
While there is no universal cure for sickle cell disease, Rushing explained a variety of curative methods that have been proven effective on some patients and cases. The two major methods are bone marrow transplants, typically between siblings, and gene therapy that changes the expression of certain genes to produce healthy blood cells that function properly, she said.
Rushing said that her work would include creating “bundles” of tools required for around 12 different EDs in line with the guidelines they require and observing how treatment of sickle cell individuals with VOCs progresses, especially in times of crises.
“The goal is to get their pain medication and treatment intitiated within 30 minutes of them being triaged, but that’s very rare (at the moment),” Rushing said. “We’re trying to see: if we give (Emergency Departments) specific tools for (them) that’s aligned with what their ED needs, will (they) be more likely to meet that guideline?”
